{"id":128381,"date":"2022-03-29T10:38:50","date_gmt":"2022-03-29T14:38:50","guid":{"rendered":"https:\/\/44.250.171.167\/?p=128381"},"modified":"2022-10-05T06:16:52","modified_gmt":"2022-10-05T10:16:52","slug":"sun-pharma-research-tear-sheet-q3-fy-2022","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/sun-pharma-research-tear-sheet-q3-fy-2022\/","title":{"rendered":"Sun Pharma Research Tear Sheet Q3 FY 2022"},"content":{"rendered":"\n

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company. The company was incorporated in 1983. It has its headquarter in Mumbai, Maharashtra India. The company deals with Pharmaceuticals, Branded generic drugs, over-the-counter drugs, Speciality drugs OTCs, APIs and ARVs. Around 72% revenue comes from the United States. The company has its operation in India, the US, Asia, Africa, Australia and Europe. The shares are traded both on BSE and NSE.<\/p>\n\n\n\n

( Rs` in Million)<\/td>Q3 FY 2022<\/td>Q3 FY 2021<\/td><\/tr>
Total Formulations<\/td>92,823.90<\/td>83,220.40<\/td><\/tr>
Total Sales<\/td>98,141.70<\/td>95,567.40<\/td><\/tr>
Total R&D Expenditure<\/td>5,471.00<\/td>5,364.10<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Highlights of Q3FY22<\/u><\/strong><\/p>\n\n\n\n

Consolidated sales from operations at Rs. 98,142 million, grew 11%.<\/p>\n\n\n\n

Formulation sales  increased by 15% to Rs. 31,676 million<\/p>\n\n\n\n

US formulation sales at US$ 397 million, grew 6%.<\/p>\n\n\n\n

Emerging Markets formulation sales at US$ 239 million, increased by 17%.<\/p>\n\n\n\n

Rest of World formulation sales at US$ 181 million, grew 3%.<\/p>\n\n\n\n

EBITDA increased by 8%  to  Rs. 25,574 million.<\/p>\n\n\n\n

EBITDA margin stood at 26.1%.<\/p>\n\n\n\n

Net profit for the quarter was at Rs. 20,588 million, increased 11% YoY.<\/p>\n\n\n\n

Cash Position<\/u><\/strong><\/p>\n\n\n\n

The company has a positive cash flow, which has helped the company in further investing and drive itself as a recognized brand in India.<\/p>\n\n\n\n

India Business<\/u><\/strong><\/p>\n\n\n\n

In India sale of formulation increased by 15% to Rs 31,676 million. Over the period of 9 months sales increased by 26 % to 96,637 million.  In Q3FY22, the company launched 25 new products in the Indian market.<\/p>\n\n\n\n

US Formulations (including Taro)<\/u><\/strong><\/p>\n\n\n\n

Formulation sales increased by 6% to  US$ 397 million and contributing 30% of total consolidated sales.<\/p>\n\n\n\n

Taro Performance<\/u><\/strong><\/p>\n\n\n\n

Taro posted sales of US$ 139 million, which is nearly flat YoY. The sale has been impacted due to impact from the settlement and loss contingencies charges in both periods.<\/p>\n\n\n\n

Emerging Markets<\/u><\/strong><\/p>\n\n\n\n

Formulation sales in Emerging Markets increased by 18% to US$ 239 million. In the past 9 months sales were US$ 700 million, grew 19%.<\/p>\n\n\n\n

Active Pharmaceutical Ingredients (API)<\/u><\/strong><\/p>\n\n\n\n

External sales of API increased by 5% to Rs. 4,710 million. API business  has improved vertical integration and continuity of supply chain for our formulations business.<\/p>\n\n\n\n

Conference Call Highlights<\/u><\/strong><\/p>\n\n\n\n

Management Updates<\/u><\/strong><\/p>\n\n\n\n

Market share has increased to 8.6% as per AIOCD AWACS data. On a MAT basis, market share is at 8.2% as per AIOCD AWACS data.<\/p>\n\n\n\n

As per SMSRC report it has ranked  No.1 ranked, by prescriptions, with 11 different doctor categories.<\/p>\n\n\n\n

Declared an interim dividend of Rs. 7.0 per share against the Rs.5.50 per share declared last year.<\/p>\n\n\n\n

The r current generic pipeline for the US market includes 88 ANDAs and 13 NDAs are still awaiting  for approval by the US FDA.<\/p>\n\n\n\n

Business Updates<\/u><\/strong><\/p>\n\n\n\n

Sun Pharma has decided to set up a new manufacturing plant in Andhra Pradesh.<\/p>\n\n\n\n

Sun Pharma is launching Molnupiravir under brand name Molxvir.<\/p>\n\n\n\n

Sun Pharmaceutical Industries is recalling over 1.10 lakhs bottles of a generic medication which is used in the treatment of erectile dysfunction.<\/p>\n","protected":false},"excerpt":{"rendered":"

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company. The company was incorporated in 1983. It has its headquarter in Mumbai, Maharashtra India. The company deals with Pharmaceuticals, Branded generic drugs, over-the-counter drugs, Speciality drugs OTCs, APIs and ARVs. Around 72% revenue comes from the United States. The company has its operation in India, the US, Asia, Africa, […]<\/p>\n","protected":false},"author":1796,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[6352,9908],"tags":[9138,1115,8749],"class_list":["post-128381","post","type-post","status-publish","format-standard","hentry","category-research-summary","category-research-tear-sheet","tag-pharma","tag-pharmaceuticals","tag-retail-pharmacy"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":128324,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q3-fy-2022-research-tear-sheet\/","url_meta":{"origin":128381,"position":0},"title":"Aurobindo Pharma Q3 FY 2022 Research Tear Sheet","author":"sreerupa","date":"March 23, 2022","format":false,"excerpt":"Aurobindo Pharma Limited\u00a0is an Indian\u00a0pharmaceutical company. It is based in \u00a0HITEC City,\u00a0Hyderabad, India. It was incorporated in 1986. The pharmaceutical products include generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses and animal health. The company markets its products in more 125+ countries by Pfizer and AstraZeneca plc. The shares are\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":128318,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-q3-fy-2022-research-tear-sheet\/","url_meta":{"origin":128381,"position":1},"title":"Dr. Reddy’s Laboratories Q3 FY 2022 Research Tear Sheet","author":"sreerupa","date":"March 22, 2022","format":false,"excerpt":"Dr. Reddy's Laboratories\u00a0are an Indian multinational\u00a0pharmaceutical\u00a0company. The company is headquartered in Hyderabad, Telangana, India and Princeton,\u00a0New Jersey, U.S. \u00a0It was incorporated in 1984. The founder is Kallam Anji Reddy. The company has its operation worldwide. The products include Pharmaceuticals,\u00a0generic drugs,\u00a0over-the-counter drugs,\u00a0vaccines,\u00a0diagnostics and Biologics. The stocks are traded on NSE, BSE\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":130478,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q4-fy-2022-research-tear-sheet\/","url_meta":{"origin":128381,"position":2},"title":"Aurobindo Pharma Q4 FY 2022 Research Tear Sheet","author":"sreerupa","date":"June 6, 2022","format":false,"excerpt":"Aurobindo Pharma Limited is an Indian pharmaceutical company. It was established in the year 1986. The founders include Mr. P.V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals. The company started its operation in the year 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":130953,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceuticals-industries-ltd-q4-fy-2022-research-summary\/","url_meta":{"origin":128381,"position":3},"title":"Sun Pharmaceuticals Industries Ltd. Q4 FY 2022 Research Summary","author":"sreerupa","date":"July 6, 2022","format":false,"excerpt":"Overview Sun Pharmaceutical Industries Limited is an Indian pharmaceutical company. The headquarters is situated in Mumbai, Maharashtra. It was incorporated in 1983. The founder is Dilip Sanghvi. It is the largest Indian Pharma company in the US, and the 4th\u00a0largest generic company globally. The company has its operation in 44\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":133199,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q1-fy-2023-research-tear-sheet\/","url_meta":{"origin":128381,"position":4},"title":"Aurobindo Pharma Limited Q1 FY 2023 Research Tear Sheet","author":"sreerupa","date":"August 15, 2022","format":false,"excerpt":"Stock Data Ticker: AUROPHARMA Exchange :NSE and BSE Industry: Automobile Price Performance Last 7 days\u00a0\u00a0\u00a0 4.36% YTD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 -19.19% Last 12 months\u00a0\u00a0\u00a0\u00a0 -28.17% It will be beneficial to invest in the stocks of Aurobindo Pharma. The company enjoys a \u00a0healthy\u00a0ROE of\u00a021.49% ROE which is an\u00a0 important financial parameter. The company has\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":131750,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-ltd-research-tear-sheet-q1-fy-23\/","url_meta":{"origin":128381,"position":5},"title":"Gland Pharma Ltd Research Tear Sheet Q1 FY 23","author":"sreerupa","date":"July 27, 2022","format":false,"excerpt":"Gland Pharma Ltd is an Indian Pharmaceutical company. It was established in 1978,\u00a0at Hyderabad, India. The founder is PVN Raju. It has expanded its operation across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. The primary focus of the company is development, manufacturing and marketing\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/128381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1796"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=128381"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/128381\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=128381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=128381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=128381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}